Elena Garbero1, Sergio Livigni2, Fiorenza Ferrari3,4, Stefano Finazzi1, Martin Langer5, Paolo Malacarne6, Manlio Cosimo Claudio Meca7, Sabino Mosca2, Carlo Olivieri8, Marco Pozzato9, Carlotta Rossi10, Mario Tavola11, Marina Terzitta12, Bruno Viaggi13, Guido Bertolini1. 1. Laboratorio di Epidemiologia Clinica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS: Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, 24020, Ranica, BG, Italy. 2. SC Anestesia Rianimazione Ospedale San Giovanni Bosco, ASL Città Di Torino, Torino, Italy. 3. Department of Anaesthesia and Intensive Care Unit, I.R.C.C.S. San Matteo Hospital and University of Pavia, Pavia, Italy. 4. Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy. 5. Emergency NGO, Milano, Italy. 6. U.O. Anestesia e Rianimazione 6, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. 7. Dipartimento Grandi Traumi, Unità Operativa di Anestesia e Rianimazione, Ospedale Maurizio Bufalini di Cesena, Cesena, Italy. 8. Ospedale Sant'Andrea, Anesthesia and Intensive Care, Vercelli, VC, Italy. 9. Struttura Complessa Universitaria di Nefrologia e Dialisi-CMID, Ospedale San Giovanni Bosco, ASL Città Di Torino, Torino, Italy. 10. Laboratorio di Epidemiologia Clinica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS: Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, 24020, Ranica, BG, Italy. carlotta.rossi@marionegri.it. 11. SC Anestesia E Rianimazione, ASST-Lecco, Lecco, Italy. 12. Department of Anesthesia and Intensive Care, Morgagni-Pierantoni Hospital, Forlì, Italy. 13. Neuroanestesia e Rianimazione AOU Careggi, Florence, Italy.
Abstract
PURPOSE: This study aimed at evaluating the efficacy and safety of high-dose (> 0.2 L/kg of treated plasma per day) coupled plasma filtration-adsorption (CPFA) in treating patients with septic shock. METHODS: Multicentre, randomised, adaptive trial, performed in 12 Italian intensive care units (ICUs). Patients aged 14 or more, admitted to the ICU with septic shock, or had developed it during the stay were eligible. The final outcome was mortality at discharge from the last hospital at which the patient received care. RESULTS: Between May 2015, and October 2017, 115 patients were randomised. The first interim analysis revealed a number of early deaths, prompting an unplanned analysis. Last hospital mortality was non-significantly higher in the CPFA (55.6%) than in the control group (46.2%, p = 0.35). The 90-day survival curves diverged in favour of the controls early after randomisation and remained separated afterwards (p = 0.100). An unplanned analysis showed higher mortality in CPFA compared to controls among patients without severe renal failure (p = 0.025); a dose-response relationship was observed between treated plasma volume and mortality (p = 0.010). CONCLUSION: The COMPACT-2 trial was stopped due to the possible harmful effect of CPFA in patients with septic shock. The harmful effect, if present, was particularly marked in the early phase of septic shock. Patients not requiring renal replacement therapy seemed most exposed to the possible harm, with evidence of a dose-response effect. Until the mechanisms behind these results are fully understood, the use of CPFA for the treatment of patients with septic shock is not recommended.
PURPOSE: This study aimed at evaluating the efficacy and safety of high-dose (> 0.2 L/kg of treated plasma per day) coupled plasma filtration-adsorption (CPFA) in treating patients with septic shock. METHODS: Multicentre, randomised, adaptive trial, performed in 12 Italian intensive care units (ICUs). Patients aged 14 or more, admitted to the ICU with septic shock, or had developed it during the stay were eligible. The final outcome was mortality at discharge from the last hospital at which the patient received care. RESULTS: Between May 2015, and October 2017, 115 patients were randomised. The first interim analysis revealed a number of early deaths, prompting an unplanned analysis. Last hospital mortality was non-significantly higher in the CPFA (55.6%) than in the control group (46.2%, p = 0.35). The 90-day survival curves diverged in favour of the controls early after randomisation and remained separated afterwards (p = 0.100). An unplanned analysis showed higher mortality in CPFA compared to controls among patients without severe renal failure (p = 0.025); a dose-response relationship was observed between treated plasma volume and mortality (p = 0.010). CONCLUSION: The COMPACT-2 trial was stopped due to the possible harmful effect of CPFA in patients with septic shock. The harmful effect, if present, was particularly marked in the early phase of septic shock. Patients not requiring renal replacement therapy seemed most exposed to the possible harm, with evidence of a dose-response effect. Until the mechanisms behind these results are fully understood, the use of CPFA for the treatment of patients with septic shock is not recommended.
Authors: C Tetta; L Gianotti; J M Cavaillon; M L Wratten; M Fini; M Braga; P Bisagni; G Giavaresi; R Bolzani; R Giardino Journal: Crit Care Med Date: 2000-05 Impact factor: 7.598
Authors: Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuck Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger Journal: Crit Care Med Date: 2017-03 Impact factor: 7.598
Authors: Claudio Ronco; Alessandra Brendolan; Gerhard Lonnemann; Rinaldo Bellomo; Pasquale Piccinni; Antonio Digito; Maurizio Dan; Marco Irone; Giuseppe La Greca; Paola Inguaggiato; Umberto Maggiore; Concetta De Nitti; Mary Lou Wratten; Zaccaria Ricci; Ciro Tetta Journal: Crit Care Med Date: 2002-06 Impact factor: 7.598
Authors: Jan Bakker; Eduardo Kattan; Djillali Annane; Ricardo Castro; Maurizio Cecconi; Daniel De Backer; Arnaldo Dubin; Laura Evans; Michelle Ng Gong; Olfa Hamzaoui; Can Ince; Bruno Levy; Xavier Monnet; Gustavo A Ospina Tascón; Marlies Ostermann; Michael R Pinsky; James A Russell; Bernd Saugel; Thomas W L Scheeren; Jean-Louis Teboul; Antoine Vieillard Baron; Jean-Louis Vincent; Fernando G Zampieri; Glenn Hernandez Journal: Intensive Care Med Date: 2021-12-15 Impact factor: 17.440
Authors: Gerd Klinkmann; Thomas Wild; Benjamin Heskamp; Fanny Doss; Sandra Doss; Lubomir Arseniev; Krasimira Aleksandrova; Martin Sauer; Daniel A Reuter; Steffen Mitzner; Jens Altrichter Journal: Intensive Care Med Exp Date: 2022-06-16